Information Provided By: 
Fly News Breaks for July 9, 2019
AMRN, ACST
Jul 9, 2019 | 13:34 EDT
As previously reported, Aegis analyst Nathan Weinstein initiated Acasti Pharma (ACST) with a Buy rating and $3 price target, telling investors that the company's Omega-3 therapeutic for the treatment of very high triglycerides, called CaPre, has demonstrated "interesting efficacy" in phase 2 study. Several companies have entered or could be close to entering the prescription Omega-3 space, including Amarin (AMRN), but Weinstein points to precedent cases of third and later entrants achieving market success in various therapeutic categories.
News For ACST;AMRN From the Last 2 Days
There are no results for your query ACST;AMRN
